评估免疫疗法在胃癌中的疗效：免疫检查点抑制剂的启示。
Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors.
机构信息
Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Department of Biochemistry, University of Ottawa, Ottawa K1H 8M5, ON, Canada.
出版信息
World J Gastroenterol. 2024 Aug 28;30(32):3726-3729. doi: 10.3748/wjg.v30.i32.3726.
Abstract
The emergence of immunotherapy, particularly immune checkpoint inhibitors (ICIs), represents a groundbreaking approach to treating gastric cancer (GC). However, the prognosis of GC patients receiving ICI treatment is influenced by various factors. This manuscript identified sarcopenia and myosteatosis as inde-pendent prognostic factors impacting the outcomes of GC patients treated with ICIs. Additionally, this study introduced a visual predictive model to estimate the prognosis of GC patients. If confirmed by further studies, this observation could provide valuable insights to propel the advancement of personalized clinical medicine and the integration of precision medicine practices.
摘要
免疫疗法的出现，特别是免疫检查点抑制剂（ICI）的出现，代表了治疗胃癌（GC）的一种突破性方法。然而，接受 ICI 治疗的 GC 患者的预后受到多种因素的影响。本研究确定了肌肉减少症和肌内脂肪变性是影响接受 ICI 治疗的 GC 患者结局的独立预后因素。此外，本研究引入了一个可视化预测模型来估计 GC 患者的预后。如果进一步的研究得到证实，这一观察结果可能为推动个性化临床医学的发展和精准医学实践的整合提供有价值的见解。
相似文献
1
Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors.评估免疫疗法在胃癌中的疗效：免疫检查点抑制剂的启示。
World J Gastroenterol. 2024 Aug 28;30(32):3726-3729. doi: 10.3748/wjg.v30.i32.3726.
2
Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.评估肌肉减少症和肌内脂肪浸润对接受免疫检查点抑制剂治疗的胃癌患者临床结局的影响。
World J Gastroenterol. 2024 Feb 28;30(8):863-880. doi: 10.3748/wjg.v30.i8.863.
3
Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer.免疫检查点抑制剂和微卫星不稳定性在胃癌中的应用。
World J Gastroenterol. 2024 Jun 7;30(21):2734-2739. doi: 10.3748/wjg.v30.i21.2734.
4
Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.开发和解释一种基于病理组学的集成模型，用于预测胃癌对免疫治疗的反应。
J Immunother Cancer. 2024 May 15;12(5):e008927. doi: 10.1136/jitc-2024-008927.
5
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值：荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
6
Advances in clinical immunotherapy for gastric cancer.胃癌临床免疫治疗进展。
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188615. doi: 10.1016/j.bbcan.2021.188615. Epub 2021 Aug 14.
7
Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.进行性肌肉减少症和肌内脂肪增多症可预测接受免疫检查点抑制剂治疗的晚期 HCC 患者的预后。
Front Immunol. 2024 Apr 16;15:1396927. doi: 10.3389/fimmu.2024.1396927. eCollection 2024.
8
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer.免疫检查点抑制剂在胃癌免疫治疗中的应用。
Immunotherapy. 2023 Feb;15(2):101-115. doi: 10.2217/imt-2022-0080. Epub 2023 Jan 4.
9
An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer.一种用于晚期胃癌预后评估和免疫治疗选择的抗原加工和呈递特征。
Front Immunol. 2022 Oct 14;13:992060. doi: 10.3389/fimmu.2022.992060. eCollection 2022.
10
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.基于免疫检查点分子和免疫检查点抑制剂的胃癌免疫治疗——叙述性综述。
Int J Mol Sci. 2024 Jun 12;25(12):6471. doi: 10.3390/ijms25126471.
引用本文的文献
1
The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer.年龄对转移性非小细胞肺癌患者免疫检查点抑制剂治疗效果的影响
Geriatrics (Basel). 2025 Jun 27;10(4):85. doi: 10.3390/geriatrics10040085.
2
Integrated single-cell and transcriptome sequencing data reveal the value of IL1RAP in gastric cancer microenvironment and prognosis.整合单细胞和转录组测序数据揭示IL1RAP在胃癌微环境和预后中的价值。
Front Oncol. 2025 May 15;15:1584619. doi: 10.3389/fonc.2025.1584619. eCollection 2025.
3
Predictive role of inflammatory markers for the efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer.炎症标志物对晚期胃癌一线免疫治疗联合化疗疗效的预测作用
Discov Oncol. 2025 Apr 26;16(1):618. doi: 10.1007/s12672-025-01857-0.
本文引用的文献
1
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.胃癌免疫抑制微环境异质性：对治疗开发的启示。
Trends Cancer. 2024 Jul;10(7):627-642. doi: 10.1016/j.trecan.2024.03.008. Epub 2024 Apr 9.
2
Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.评估肌肉减少症和肌内脂肪浸润对接受免疫检查点抑制剂治疗的胃癌患者临床结局的影响。
World J Gastroenterol. 2024 Feb 28;30(8):863-880. doi: 10.3748/wjg.v30.i8.863.
3
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.胃癌免疫治疗的预测生物标志物：现状与展望。
Int J Mol Sci. 2023 Oct 18;24(20):15321. doi: 10.3390/ijms242015321.
4
The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer.肌肉减少症和肌少症性肥胖对胃癌患者生存的影响。
BMC Cancer. 2023 Sep 28;23(1):911. doi: 10.1186/s12885-023-11423-y.
5
ACTA2 Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer.ACT A2 表达预测生存并与胃癌对免疫检查点抑制剂的反应相关。
Clin Cancer Res. 2023 Mar 14;29(6):1077-1085. doi: 10.1158/1078-0432.CCR-22-1897.
6
Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis.肌内脂肪浸润对胃癌患者总生存预后价值的荟萃分析：一项试验序贯分析。
Nutrition. 2023 Jan;105:111866. doi: 10.1016/j.nut.2022.111866. Epub 2022 Oct 14.
7
Characteristics of gastric cancer around the world.世界各地胃癌的特征。
Crit Rev Oncol Hematol. 2023 Jan;181:103841. doi: 10.1016/j.critrevonc.2022.103841. Epub 2022 Oct 11.
8
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.免疫检查点抑制剂的肿瘤免疫疗法；优缺点。
Cell Commun Signal. 2022 Apr 7;20(1):44. doi: 10.1186/s12964-022-00854-y.
9
Advances in clinical immunotherapy for gastric cancer.胃癌临床免疫治疗进展。
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188615. doi: 10.1016/j.bbcan.2021.188615. Epub 2021 Aug 14.
10
Computed Tomography-Derived Myosteatosis and Metabolic Disorders.计算机断层扫描衍生的肌少症与代谢紊乱。
Diabetes Metab J. 2021 Jul;45(4):482-491. doi: 10.4093/dmj.2020.0277. Epub 2021 Jul 30.
Zotero 插件